Etsy shares plunge 12% on decline in gross merchandise sales
By Jon Swartz
Etsy Inc.'s stock plunged 12% in after-hours trading Wednesday after the company posted quarterly results that included a decline in gross merchandise sales.
Etsy (ETSY) reported net income of $63 million, or 48 cents a share, for its first fiscal quarter, compared with $74.5 million, or 53 cents a share, in the comparable quarter a year ago.
Total revenue edged up to $645.9 million from $640.9 million in the year-ago quarter. Specifically, GMS - a key indicator of growth - declined 3.7% on a year-over-year basis to $2.99 billion.
The consensus of analysts surveyed by FactSet had forecast net income of 48 cents a share on revenue of $646 million.
"Our first-quarter performance, while in line with our guidance, was pressured by the challenging environment for consumer discretionary products, which continues to be a headwind to Etsy marketplace growth," Chief Executive Josh Silverman said in a statement announcing the results.
Shares of Etsy have tumbled 14% this year through Wednesday, while the benchmark S&P 500 index SPX is up 5%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-01-24 2019ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks